2 terminated. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Terminated 2 |
| Phase 1 | 1 | Terminated 1 |
Follow repotrectinib: new trials by email Literature Review of repotrectinib trials Research Report on repotrectinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone Receptor-positive Human Epidermal Growth Factor 2-negative Metastatic Invasive LObular Carcinoma Who Received a Prior Endocrine Therapy in Combination With Cyclin-dependent Kinase 4 and 6 Inhibitor (REPLOT Trial) Fulvestrant, Repotrectinib - Hormone Receptor-positive Human Epidermal Growth Factor 2-negative, Metastatic Invasive LObular Carcinoma | Phase 2 | Terminated | M.D. Anderson Cancer Center | 6 | 2024-08-08 | 2026-01-05 |
| A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors TPX-0005, Trametinib - KRAS Mutation-Related Tumors, Metastatic Solid Tumor | Phase 1 / Phase 2 | Terminated | Turning Point Therapeutics, Inc. | 9 | 2021-09-23 | 2024-04-02 |
Carcinoma, Lobular (1) · Neoplasm Metastasis (1)
M.D. Anderson Cancer Center (1) · Turning Point Therapeutics, Inc. (1)
United States (2)